中国临床药理学杂志2024，Vol.40Issue(19)：2801-2805,5.DOI:10.13699/j.cnki.1001-6821.2024.19.009
胞磷胆碱治疗卒中后认知障碍患者的临床研究
Clinical trial of citicoline in the treatment of patients with post-stroke cognitive impairment
摘要
Abstract
Objective To observe the clinical efficacy of citicoline sodium tablets combined with huperzine A tablets in the treatment of patients with cognitive impairment after stroke,and to explore the influence on neurological function and serum levels of vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF).Methods Patients with cognitive impairment after stroke were classified into control group and treatment group according to cohort method.The control group was given oral administration of huperzine A tablets 0.1-0.2 mg for twice a day,while the treatment group was given 0.2 g citicoline sodium tablets orally for three times a day on the basis of the control group.Both groups of patients were treated for 12 weeks.The clinical efficacy,cognitive function[Mini-Mental State Examination(MMSE),National Institute of Health stroke scale,Barthel index],neurological function and daily living ability and serum vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF)levels were compared and safety was evaluated.Results One hundred patients were enrolled in the experimental group and the control group.After treatment,the total effective rates in treatment group and control group were 92.00％(92 cases/100 cases)and 75.00％(75 cases/100 cases)with significant difference(P＜0.05).The MMSE scores in treatment group and control group after treatment were(23.40±2.43)and(19.35±2.51)points;the scores of National Institutes of Health Stroke Scale were(12.25±1.24)and(15.84±1.61)points;the Barthel Index scores were(71.14±8.60)and(64.26±8.33)points;VEGF levels were(191.52±14.80)and(125.73±11.48)pg·mL-1;BDNF levels were(9.47±1.59)and(8.01±1.35)ng·mL-1.There were statistically significant differences in the above indexes between the treatment group and the control group(all P＜0.05).The adverse drug reactions in the treatment group were mainly dizziness and nausea,and the adverse drug reactions in the control group were mainly dizziness and nausea.The incidence rates of adverse drug reactions in treatment group and control group were 8.00％(8 cases/100 cases)and 5.00％(5 cases/100 cases)(P＞0.05).Conclusion Citicoline sodium tablets combined with huperzine A tablets have a definite efficacy in the treatment of patients with cognitive impairment after stroke,and it has a significant improvement effect on cognitive function and neurological function of patients,with good safety.关键词
胞磷胆碱钠片/石杉碱甲片/卒中后认知障碍/神经功能/血管内皮生长因子/脑源性神经营养因子/安全性评价Key words
citicoline sodium tablet/huperzine A tablet/cognitive impairment after stroke/neurological function/vascular endothelial growth factor/brain-derived neurotrophic factor/safety evaluation分类
药学引用本文复制引用
高昶,刘燕,聂琼,王新宇,张翠翠..胞磷胆碱治疗卒中后认知障碍患者的临床研究[J].中国临床药理学杂志,2024,40(19):2801-2805,5.基金项目
国家自然科学基金项目资助项目(81901391) （81901391）
山东省政府泰山学者青年专家人才计划基金资助项目(tsqn201909145) （tsqn201909145）
山东省济宁市重点研发计划基金资助项目(2019SMNS001) （2019SMNS001）
济宁医学院贺林基金资助项目(JYHL2021MS04) （JYHL2021MS04）
